Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment

Clin Rheumatol. 1991 Mar;10(1):43-8. doi: 10.1007/BF02208032.


In a 12-month double-blind placebo-controlled trial, the effect of sulphasalazine was studied in 40 patients with ankylosing spondylitis. The treatment group showed significant improvement in pain, stiffness, sleep disturbance (p less than 0.05), finger/floor distance, erythrocyte sedimentation rate, C-reactive protein, orosomucoid and IgA levels (p less than 0.01). There was improvement in sleep disturbance (p less than 0.05), finger/floor distance and erythrocyte sedimentation rate (p less than 0.01) in the placebo group. Sulphasalazine did not retard radiological progression as measured either by plain X-ray or computerised tomographic scans. Multiple analysis of variance did not show a significant difference in disease activity indicators between the 2 groups.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analysis of Variance
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Blood Sedimentation / drug effects
  • C-Reactive Protein / metabolism
  • Cohort Studies
  • Double-Blind Method
  • Haptoglobins / metabolism
  • Humans
  • Immunoglobulin A / metabolism
  • Orosomucoid / metabolism
  • Spondylitis, Ankylosing / diagnostic imaging
  • Spondylitis, Ankylosing / drug therapy*
  • Spondylitis, Ankylosing / metabolism
  • Spondylitis, Ankylosing / pathology
  • Sulfasalazine / pharmacology
  • Sulfasalazine / therapeutic use*
  • Tomography, X-Ray Computed


  • Anti-Inflammatory Agents, Non-Steroidal
  • Haptoglobins
  • Immunoglobulin A
  • Orosomucoid
  • Sulfasalazine
  • C-Reactive Protein